These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10198796)

  • 41. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children.
    Feder HM; Beran J; Van Hoecke C; Abraham B; De Clercq N; Buscarino C; Parenti DL
    J Pediatr; 1999 Nov; 135(5):575-9. PubMed ID: 10547245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview.
    Sadziene A; Barbour AG
    Infection; 1996; 24(2):195-202. PubMed ID: 8740122
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T helper cell priming of mice to Borrelia burgdorferi OspA leads to induction of protective antibodies following experimental but not tick-borne infection.
    Zhong W; Gern L; Kramer M; Wallich R; Simon MM
    Eur J Immunol; 1997 Nov; 27(11):2942-7. PubMed ID: 9394822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice.
    Fikrig E; Telford SR; Barthold SW; Kantor FS; Spielman A; Flavell RA
    Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5418-21. PubMed ID: 1608951
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A brief history of OspA vaccines including their impact on diagnostic testing for Lyme disease.
    Wormser GP
    Diagn Microbiol Infect Dis; 2022 Jan; 102(1):115572. PubMed ID: 34763193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
    Fawcett PT; Rose CD; Budd SM; Gibney KM
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccination against Lyme borreliosis.
    Wahlberg P
    Ann Med; 1999 Aug; 31(4):233-5. PubMed ID: 10480752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype.
    Schaible UE; Wallich R; Kramer MD; Gern L; Anderson JF; Museteanu C; Simon MM
    Vaccine; 1993; 11(10):1049-54. PubMed ID: 8212826
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Lyme borreliosis--vaccines in the "pipeline"].
    Kramer M
    MMW Fortschr Med; 1999 Jun; 141(25):52-3. PubMed ID: 10897909
    [No Abstract]   [Full Text] [Related]  

  • 50. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
    Beran J; De Clercq N; Dieussaert I; Van Hoecke C
    Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA.
    Ding W; Huang X; Yang X; Dunn JJ; Luft BJ; Koide S; Lawson CL
    J Mol Biol; 2000 Oct; 302(5):1153-64. PubMed ID: 11183781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi.
    Langermann S; Palaszynski S; Sadziene A; Stover CK; Koenig S
    Nature; 1994 Dec; 372(6506):552-5. PubMed ID: 7990928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modulation of lymphocyte proliferative responses by a canine Lyme disease vaccine of recombinant outer surface protein A (OspA).
    Chiao JW; Villalon P; Schwartz I; Wormser GP
    FEMS Immunol Med Microbiol; 2000 Jul; 28(3):193-6. PubMed ID: 10865170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-OspA antibody reduces reservoir competence of mice for Borrelia burgdorferi, the agent of Lyme disease.
    Brunet LR; Katavolos P; Spielman A; Telford SR
    Med Vet Entomol; 1997 Apr; 11(2):198-200. PubMed ID: 9226653
    [No Abstract]   [Full Text] [Related]  

  • 56. Borrelia burgdorferi outer surface protein A vaccine: importance, role, and value.
    Sigal LH
    J Pediatr; 1999 Nov; 135(5):539-41. PubMed ID: 10547238
    [No Abstract]   [Full Text] [Related]  

  • 57. Killing of Borrelia burgdorferi by antibody elicited by OspA vaccine is inefficient in the absence of complement.
    Nowling JM; Philipp MT
    Infect Immun; 1999 Jan; 67(1):443-5. PubMed ID: 9864253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.
    Sikand VK; Halsey N; Krause PJ; Sood SK; Geller R; Van Hoecke C; Buscarino C; Parenti D;
    Pediatrics; 2001 Jul; 108(1):123-8. PubMed ID: 11433064
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Availability of Lyme disease vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1999 Jan; 48(2):35-6, 43. PubMed ID: 9933128
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Borrelia burgdorferi escape mutants that survive in the presence of antiserum to the OspA vaccine are killed when complement is also present.
    Solé M; Bantar C; Indest K; Gu Y; Ramamoorthy R; Coughlin R; Philipp MT
    Infect Immun; 1998 Jun; 66(6):2540-6. PubMed ID: 9596714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.